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Blood-Brain Glucose Transfer in 
Alzheimer’s disease: Effect of GLP-1 
Analog Treatment
Michael Gejl1,2,3, Birgitte Brock1,3, Lærke Egefjord1,2, Kim Vang2, Jørgen Rungby1,4 &  
Albert Gjedde  2,5,6
There are fewer than normal glucose transporters at the blood-brain barrier (BBB) in Alzheimer’s 
disease (AD). When reduced expression of transporters aggravates the symptoms of AD, the 
transporters become a potential target of therapy. The incretin hormone GLP-1 prevents the decline of 
cerebral metabolic rate for glucose (CMRglc) in AD, and GLP-1 may serve to raise transporter numbers. 
We hypothesized that the GLP-1 analog liraglutide would prevent the decline of CMRglc in AD by raising 
blood-brain glucose transfer, depending on the duration of disease. We randomized 38 patients with 
AD to treatment with liraglutide (n = 18) or placebo (n = 20) for 6 months, and determined the blood-
brain glucose transfer capacity (Tmax) in the two groups and a healthy age matched control group (n = 6). 
In both AD groups at baseline, Tmax estimates correlated inversely with the duration of AD, as did the 
estimates of CMRglc that in turn were positively correlated with cognition. The GLP-1 analog treatment, 
compared to placebo, highly significantly raised the Tmax estimates of cerebral cortex from 0.72 to 1.1 
umol/g/min, equal to Tmax estimates in healthy volunteers. The result is consistent with the claim that 
GLP-1 analog treatment restores glucose transport at the BBB.
Aging populations suffer from increased incidence of metabolic disorders and type 2 diabetes, including vascular 
disease and dementia1. Under normal circumstances, glucose molecules in the circulation enter brain tissue from 
plasma by facilitated diffusion across the two membranes of the endothelium of the blood–brain barrier (BBB). 
The facilitated diffusion is mediated mainly by the glucose transporter 1 (GLUT1), a key regulator of glucose 
transport into and out of the brain where it serves to maintain homeostasis2. Among the insulin-insensitive 
transporters, GLUT1 is abundant in the BBB and in astrocytes, while neurons primarily are served by the glucose 
transporter GLUT3. Brain glucose uptake correlates with GLUT1 levels in cerebral microvessels3–5, although 
glucose transporters other than GLUT1 are known also to operate in the BBB, including in particular the 
insulin-sensitive glucose transporter GLUT46. Although GLUT1 transport mechanistically is insulin insensitive, 
GLUT1 transport in general may be said to moderately sensitive to the presence of insulin in the sense that the 
presence of insulin in earlier studies led to a limited increase in the number of GLUT1 transporters in cell mem-
branes in specific parts of the body (muscle, thyroid gland7,8).
Alzheimer’s disease (AD) is characterized by deposits of amyloid-β (Aβ) and hyperphosphorylated tau pro-
teins that may impair neurovascular regulation, blood brain barrier (BBB) integrity9, and expression of glu-
cose transporters at the BBB6. The deposits also may aggravate the cerebral metabolic decline10 that correlates 
with impaired cognition11. Loss of glucose transporters from the BBB is known to occur before the onset of AD 
symptoms6, and PET of [18F]fluoro-2-deoxyglucose ([18F]FDG)-derived radioactivity in brain reveals progres-
sive reduction of cerebral metabolic rate of glucose CMRglc, before detection of clinical symptoms in individ-
uals with subsequently confirmed AD12. The diminished metabolism exceeds and precedes brain atrophy and 
neurodegeneration13–16.
There is evidence in AD that impaired brain glucose uptake or metabolism, or both, may be the result of 
brain insulin resistance, or down-regulation of the glucose transporters in brain required for cerebral glucose 
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uptake and metabolism17–19. This means that it is possible that glucose transport across the BBB may become 
the rate-limiting step of glucose metabolism in AD20, the disorder in which the number of glucose transporters 
is known to be reduced21,22. Thus, the decline of the CMRglc may follow the reduction of BBB glucose transport 
capacity23,24. Recent work in mice reveals that reduced expression of GLUT1 in the BBB leads to massive progres-
sion of AD neuropathology, and that GLUT1 deficiency in the endothelium initiates BBB breakdown, possibly as 
an early pathogenic step in the evolution of AD25.
The formal differences between the maximum blood-brain glucose transport capacity (Tmax) and CMRglc steps 
of the pathways of glucose metabolism mean that the two measures are unrelated in principle, as the Tmax step 
depends on the density and activity of transporters, while the CMRglc step depends on and is close to the max-
imum velocity (Vmax) of hexokinase in brain tissue. The phosphorylation of glucose (or [18F]FDG) requires the 
presence of the substrate in the tissue at a concentration consistent with the Vmax of hexokinase, but there is no 
other link between the two measures. The absence of additional links was the motivation for the analysis pre-
sented here, i.e., the determination of the transport changes potentially correlated with the progression of AD.
Recent findings by the present group of researchers show that native GLP-1 raises maximum glucose transport 
capacity in brain capillary endothelium in healthy humans2,26. In the present investigation, we hypothesized that 
the same mechanism activated by the GLP-1 analog liraglutide may act to prevent the decline of glucose metabo-
lism in patients with AD, as reported by Gejl et al.27. Restoration of mechanisms important to the neurovascular 
unit by liraglutide and prevention of further neurovascular degeneration would then avert the potential exacerba-
tion of glucose transporter deficiency in AD28, in agreement with the view that glucose transport is a potentially 
important therapeutic target of treatment in AD6,25.
The rationales of the present paper are, first, the test of the physiological impact of BBB glucose transport on 
AD progress and evolution and, second, the test of restoration of mechanisms important to the neurovascular 
unit by liraglutide and prevention of further neurovascular degeneration would then avert the potential exacer-
bation of glucose transporter deficiency in AD, in agreement with the view that glucose transport is a potentially 
important therapeutic target of treatment in AD.
On the basis of the results of GLP-1 analog treatment, and the effects on CMRglc27, we tested the hypothesis 
that liraglutide is a GLP-1 analog that raises the Tmax and the clearance from the circulation of glucose by the 
brain tissue. We determined the values of Tmax and CMRglc during AD evolution and progression, as reflected in 
measures of cognition and disease duration. Specifically, we tested the hypothesis that treatment with the GLP-1 
analog liraglutide would prevent or reduce the decline of Tmax, assessed by PET of tracer [18F]FDG derived radi-
oactivity in brain.
Results
Baseline. Group differences at baseline are listed by Gejl et al.27. Disease duration was significantly longer in 
the liraglutide group (30 ± 6 vs 15 ± 3 months). At baseline the average Tmax estimate was significantly lower in 
the treatment group (P = 0.02), compared to the placebo group, with a mean difference of 0.15 µmol/g/min, 95% 
CI of diff: 0.29; 0.017), as shown in Fig. 1. The liraglutide group was slightly younger (63.1 vs. 66.6 years, P = 0.16), 
as was the group of six cognitively normal volunteers at 63 ± 3 years29.
Group Regressions and Correlations at Baseline. Linear regressions among the variables determined at 
baseline are shown in Fig. 2: Analysis of CMRglc versus duration of AD revealed a negative correlation (P = 0.006, 
R2 = 0.23, Fig. 2A) at baseline of both groups pooled. We observed a positive correlation between CMRglc and the 
total cognition score at baseline of all members of the two groups pooled (P = 0.006, R2 = 0.23, Fig. 2B). We found 
tendencies of correlation between the Tmax estimates and the duration of disease (P = 0.05, R2 = 0.12, Fig. 2C) at 
baseline of all members of the groups pooled, nor between the Tmax estimates and total cognitive score (P = 0.83, 
Figure 1. Estimates of Tmax of two groups before and after liraglutide and placebo treatment. Ordinate Tmax 
estimates. GLP-1 analog treatment very significantly (P < 0.0001) raised the average Tmax estimate in cerebral 
cortex as a whole. The resulting value of Tmax significantly exceeded the value reached by placebo treatment.
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R2 = 0.002, not shown). We found positive linear correlation of glucose utilization fraction (GUF) and cognition 
(P = 0.01, R2 = 0.21, Fig. 2D) at baseline of both groups pooled, but no correlation between GUF and duration of 
disease (P = 0.19, R2 = 0.06, not shown), also of all members of the two groups pooled, nor between the unidi-
rectional glucose extraction fraction (GEF) and cognition or duration (P > 0.35, R2 < 0.03, not shown). We also 
found a positive linear correlation of CMRglc and Tmax (P = 0.02, R2 = 0.18, Fig. 2E).
We observed a positive correlation between the net clearance of [18F]FDG (and therefore of glucose as well) 
and the total cognitive score at baseline of both groups pooled (P = 0.02, R2 = 0.17, Fig. 2F). The correlation of the 
net clearance of [18F]FDG (and therefore of glucose) and the duration of AD was significantly negative (P = 0.007, 
R2 = 0.22, not shown) at baseline for the members of both groups pooled.
Group Variables, Changes, and Differences During and After Treatment. Gejl et al.27 reported a 
decrease in fasting plasma glucose in both groups and a significant difference of fasting plasma glucose levels 
between the two groups after six months of treatment (5.6 mM in the placebo group and 5.1 mM in the GLP-1 
analog group). Fasting plasma glucose levels in the heathy group was 5.830. We also noted significant reduction of 
systolic and diastolic blood pressures in the liraglutide group at the end of the study period.
Figure 2. Relationship between duration of AD and CMRglc (A), total cognitive score and CMRglc (B), duration 
of AD and Tmax, (C), total cognitive score and GUF (D), Tmax and CMRglc (E), and total cognitive score and net 
clearance of [18F]FDG. The points representing the averages of the healthy control group were not included in 
the analysis.
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We observed no change of the cortical Tmax estimate (P = 0.24, mean difference 0.093 µmol/g/min, 95% CI of 
difference: −0.037; 0.22) in the placebo group during the six months of treatment. In the GLP-1 analog treatment 
group, the Tmax estimate increased significantly after the 6 months of treatment (P < 0.0001, mean difference 0.34 
µmol/g/min, 95% CI of the difference 0.20; 0.49), as shown in Fig. 1 of both estimates. After the six months, the 
Tmax estimates of the two groups no longer differed significantly (P = 0.24). The estimates of Tmax increased signif-
icantly more in the liraglutide treated group than in the placebo group (P = 0.0002, mean difference 0.25 µmol/g/
min, 95% CI of the difference 0.13; 0.37), as shown in Figs 1 and 3. In healthy volunteers, the Tmax estimates aver-
aged 1.022 umol/g/min, as shown in Fig. 3.
The maximum observable clearance is the ratio of an estimate of Tmax to the corresponding estimate of the 
Michaelis half-saturation concentration Kt, i.e., the T K/ tmax  ratio, equal to the abscissa intercept of the 
Eadie-Hofstee plot. The ratio is a measure of the highest attainable transport capacity at the present affinity of the 
transporters to glucose. The maximum clearance estimates increased with the duration of disease, as shown in 
Fig. 4 for the placebo group at baseline and 6 months, and for liraglutide treatment group at baseline. The six 
months of liraglutide treatment reversed the trend by returning the ratio to the value of the placebo group at 
baseline. The corresponding estimates of the Michaelis half-saturation concentration are listed in the legend to 
Fig. 1.
The estimates of net clearance of [18F]FDG and glucose (K* and K) did not change in the placebo group 
(P = 0.53), but increased with borderline significance in the liraglutide group (P = 0.049), as listed in Table 1. 
We calculated the estimates of CMRglc listed in Table 1 by regional kinetic analysis. The estimates confirmed the 
decrease in the placebo group (P = 0.05) and unaltered CMRglc in the liraglutide group (P = 0.58) reported by Gejl 
et al.27. The CMRglc estimates of the healthy control group was 0.31 ± 0.062 umol/g/min29.
Discussion
Analogs of the glucagon-like peptide-1 (GLP-1) hold promise as a novel approach to the treatment of neuro-
degenerative disorders such as AD31. The analogs target cerebral metabolism and neurodegeneration in animal 
models, with potential translation to afflicted humans27. In the present analysis of findings obtained in patients 
with AD, we discovered a highly significant effect of the GLP-1 analog liraglutide on the blood-brain glucose 
transport capacity. In the patients, the estimates of blood-brain glucose transport capacity correlated with the 
estimates of glucose consumption (CMRglc). We confirmed the natural disease progression in the study popula-
tion, determined by a negative correlation between disease duration and neuronal activity measured as glucose 
metabolism and the tendency of the Tmax estimates to decline with increasing duration of disease. The estimates 
of metabolism in turn correlated positively with measures of cognition, including the trend towards decreased 
estimates of cortical CMRglc in the members of the placebo treatment group. The net clearances of [18F]FDG and 
glucose correlated positively with cognition and negatively with duration at baseline and increased significantly 
Figure 3. The GLP-1 analog treatment appeared to reduce the effects of disease duration. The results are 
consistent with the claims (1) that the maximum blood-brain transfer capacity declines with duration of 
Alzheimer’s disease, and (2) that GLP-1 analog treatment raises the GLUT1 activity in the barrier as a potential 
future target for treatment of the neurovascular dysfunction in Alzheimer’s disease. Estimates of Kt averaged 
9.3 mM (± 0.28 RSDR, robust standard deviation of residuals) in the placebo treated group at baseline, 10.1 mM 
(± 0.19 RSDR) at six months, and 5.9 mM (± 0.18 RSDR) in the liraglutide group at baseline, and 11.1 mM 
(± 0.25 RSDR) at six months of treatment. The points representing the averages of the healthy control group 
were not included in the analysis.
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with treatment in the liraglutide group. The glucose utilization fraction (GUF) correlated positively with cogni-
tion and in the treatment group numerically exceeded the corresponding estimates of placebo group.
Glucose transport across the BBB is the net result of glucose fluxes in the two directions across both mem-
branes of the capillary endothelium, mediated by glucose transporters of which GLUT1 predominates32. The 
fluxes across the membranes of the BBB can be regulated (1) by changing the concentration gradients in the direc-
tions of the tissue, thereby changing the differences between the fluxes in both directions across the endothelial 
membranes, (2) by changing the affinity of the transporters separately or jointly for the multiple substrates33, or 
(3) by changing the number or density of transporters by insertion of new proteins independently of the capillary 
surface area34. The last of the three mechanisms determines the magnitude of the maximum transport capacity 
(Tmax). The present results indicate that changes associated with the GLUT1 transporter can occur by changes of 
the density of GLUT1 or by changes of the half-saturation or affinity constants. In animal studies, reports sug-
gest that regulation of GLUT1 is essential to preservation of proper brain capillary networking, blood flow, and 
endothelial integrity, as well as to neuronal function and structure25. Recent results imply that reduced glucose 
availability in the central nervous system directly triggers behavioral deficits related to the development of neuro-
pathology and synaptic dysfunction mediated by hyperphosphorylated tau proteins35. The GLUT1 deficiency syn-
drome introduced by, among other authors of the report by DeVivo and Harik36, is an important example of an 
extreme version of GLUT1 deficiency that leads to a number of neurodegenrative features, of which Alzheimer’s 
disease may be said to be a milder example.
The present results agree with reports of healthy subjects26, although little is known of the specific effects 
of GLP-1 and its analogs on brain glucose transport. The claim of a direct effect of GLP-1 or its analogs on the 
transport of glucose across the BBB therefore remains speculative, but recent work by Jais et al.37 unveils the novel 
mechanism that vascular endothelial growth factor (VEGF) from macrophages at the BBB restores the presence 
of GLUT1 to baseline values, maintains CMRglc, and prevents loss of function. It is of particular interest that 
Figure 4. Maximum clearance as function of disease duration of all baseline and placebo treatment 
groups, and separately for liraglutide group treated for 6 months. Abscissa: Duration (months). Ordinate: 
Maximum clearance calculated as average of Tmax/Kt ratios for the four groups. Curve represents best fit of 
exponential growth equation Y = Yo + A exp(−k(X − Xo)) with R2 = 0.4 and parameters + standard errors of 
Yo = 9.28 + 0.08 ml/hg/min, A = 0.12 + 0.49 ml/hg/min, and k = 0.23 + 0.27 min−1, with Xo fixed at 16.4 months, 
the average duration of the placebo group members at baseline. The points representing the averages of the 
healthy control group were not included in the analysis.
Placebo Vb K1* K2* K3* Jglc K CMRglc Ctissue K2 J2 K1 GUF GEF
mean baseline 0.066 0.094 0.107 0.062 0.375 0.035 0.268 1.448 0.073 0.107 0.064 0.115 0.165
sd 0.020 0.016 0.014 0.015 0.058 0.010 0.071 0.589 0.010 0.051 0.011 0.031 0.042
mean 6 month 0.062 0.097 0.117 0.062 0.370 0.033 0.248 1.547 0.079 0.122 0.065 0.106 0.160
sd 0.014 0.013 0.029 0.024 0.059 0.008 0.062 0.516 0.019 0.049 0.009 0.029 0.043
ttest 0.35 0.53 0.20 0.37 0.69 0.53 0.05 0.36 0.20 0.12 0.53 0.21 0.49
Liraglutide Vb K1* K2* K3* Jglc K CMRglc Ctissue K2 J2 K1 GUF GEF
mean baseline 0.065 0.102 0.131 0.064 0.383 0.034 0.246 1.531 0.089 0.137 0.069 0.106 0.165
sd 0.018 0.020 0.021 0.007 0.083 0.009 0.059 0.413 0.014 0.044 0.013 0.033 0.051
mean 6 month 0.069 0.105 0.117 0.066 0.361 0.038 0.250 1.382 0.079 0.111 0.071 0.126 0.179
sd 0.016 0.014 0.024 0.017 0.057 0.005 0.036 0.430 0.016 0.047 0.009 0.035 0.035
ttest 0.46 0.49 0.09 0.99 0.26 0.049 0.58 0.36 0.09 0.06 0.49 0.12 0.25
Table 1. Kinetic analysis results. *paired test, nonparametric.
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GLP-1 is coupled to augmented VEGF generation38. The most abundant GLUT in the BBB is GLUT-1, but low 
levels of other GLUTs (including the insulin sensitive GLUT-4) have been reported6.
The present observation of increased estimates of Tmax in principle can be explained by increase of the number 
of GLUTs, prompted by liraglutide, or by subsequent increased postprandial insulin levels. Liraglutide raises 
GLUT-4 levels in the periphery via an AMPK-dependent mechanism that is independent of insulin39, but recent 
reports suggest that astrocytic insulin receptors modulate GLUT1 expression, and consequently GLUT1 protein 
levels at the cell membrane40. Moreover, insulin signalling in hypothalamic astrocytes supposedly contributes to 
glucose sensing in the central nervous system and systemic glucose metabolism by regulation of glucose uptake 
across the BBB41, in agreement with the present results, as GLP-1 potentially co-regulates the expression of hypo-
thalamic insulin, although the mechanism is debated42. We note that liraglutide does not appear to cross the BBB 
of cerebral cortex43, suggesting direct effects on the barrier, or peripheral effects of receptor stimulation, e.g., 
anti-inflammatory44, potentially interfering with the reported decline of CMRglc in AD.
The average value of the Tmax of 1.02 umol/g/min in healthy volunteers agreed with values from Choi et al.45 
who fitted the standard Michaelis–Menten equation to the measured brain glucose concentrations. As a function 
of plasma glucose, the regression yielded values of Michaelis constant Kt of 11.8 ± 1.6 mmol/L and a Tmax/CMRglc 
ratio of 4.7 ± 0.14. Similarly, De Graaf et al.46 reported values of the Tmax/CMRglc ratio that averaged 3.2 ± 0.10 
and 3.9 ± 0.15 for gray matter and white matter using the standard transport model, with Kt of 6.2 ± 0.85 and 
7.3 ± 1.1 mmol/L for gray matter and white matter. For an average whole-brain glucose consumption rate of 0.25 
umol/g/min, the corresponding Tmax estimates average close to 1 umol/g/min with an average Michaelis con-
stant of 8.4 mmol/l. Direct Tmax estimates by Brooks et al.; Feinendegen et al., and Blomqvist et al.47–49 averaged 
0.9 umol/g/min, with an average Michaelis constant of 3.7 mM. Measurements of blood-brain unidirectional 
cleance of glucose (K1)48–53, averaged 0.08 ml/g/min for K1 and 0.34 umol/g/min for the blood-brain glucose flux 
(J1 = K1 Ca). The canonical Tmax estimate for glucose transport across the human blood-brain barrier was listed 
by Gjedde54 as 1 umol/g/min.
The prevention of decline of CMRglc is associated with an effect of liraglutide on the Tmax estimates. The effect 
may represent a possible reversal of the expected down-regulation of the brain glucose transporters that are 
required for glucose uptake and metabolism in the brain19. We note that the finding of reduced glucose transport 
capacity in AD presented here may also to some extent reflect lower neuronal activity and/or loss of neuronal cell 
mass, raising the issue of the unresolved identification of cause and effect. Although the present population of 
patients only revealed a tendency towards a direct correlation with disease duration, animal studies show that 
BBB breakdown occurs before the development of functional deficits25. The reversal of the duration-related 
increase of the estimates of maximum clearance (T K/ tmax ) is a further indication that a potentially important 
mechanism of disease advance with duration is the increase of affinity of the transporters to glucose that causes 
the maximum clearance to increase, as the maximum transport capacity declines. The treatment with liraglutide 
reverses both of these trends, jointly expressed as a normalization of the estimates of maximum clearance.
Aging and neurodegenerative disorders have been shown to be associated with increased lactate concen-
tration55, and lactate has been observed to play an important role in the regulation of cerebral blood flow56,57, 
implying that higher lactate production is associated with higher blood flow rates. One prediction from this 
association is higher blood flow rates relative to glucose consumption in these states, including lowering of the 
glucose utilization or net extraction fraction (GUF) in aging and neurodegenerative disorders. In agreement with 
these findings, we report a positive correlation between cognitive scores and GUF estimates in the patients from 
both groups at baseline. In addition, we report that the GLP-1 analog treatment is associated with insignificantly 
higher GUF estimates and significantly increased net clearances of [18F]FDG and glucose in the treatment group, 
compared to the placebo group, with numerical tendencies towards an increase of GUF estimates in the treatment 
group and a decline of GUF estimates in the placebo group (although neither trend is significant).
As predicted, the estimates of CMRglc declined with disease duration, indicating the natural progression of the 
disease in this group of patients, signifying the conclusion that GLP-1 receptor stimulation halts the progression 
of Alzheimer’s disease, in association with a very significant increase of the Tmax estimates. The decline of CMRglc 
estimates coincided with the decline of cognitive functioning, as previously reported11. As the restoration of brain 
glucose levels and metabolism is likely to positively influence AD pathology35, this is a potentially novel approach 
to prevention or termination of disease progression.
Limitations. The AD duration measure determined as the time from definite diagnosis naturally has consid-
erable uncertainty. The fact that the inclusion criteria were solely clinical, potentially limits the accuracy of the 
duration measure58. A further caveat is the small subject sample sizes. Regardless of blinding and randomization, 
minor differences in the baseline characteristics of the treated and placebo groups influence subsequent disease 
progression and hence affect the therapeutic impact. In larger studies, randomization would be more likely to 
balance the treated and untreated groups. Despite the extensive evidence of the relation between CMRglc and 
cognition, also as reported in a study of this size, the interpretation of measures of cognition in the current paper 
is of course speculative. While the trial was conducted as a randomized, placebo-controlled, double-blinded 
intervention study, and the PET analysis was carried out by an author blinded to the group and subject definitions 
(KV), the findings are the results of post-hoc analysis and as such were not obtained in a blinded fashion.
Conclusion
In the present study, we report the evidence that prevention of the decline of CMRglc is associated with improve-
ment of BBB glucose transport capacity, detected as differences of estimates of the maximum capacity of 
blood-brain transfer of glucose (Tmax), interpreted as a crucial element of disease progression and duration, 
responsible for possible limitations of nutrient delivery. The evidence extends the previous discovery of an effect 
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of GLP-1 on maximum blood-brain glucose transfer capacity in healthy human volunteers, reported by Gejl et 
al.26. The change of Tmax estimates occurred in relation to changes of the net clearance of glucose, and net glucose 
consumption (CMRglc), both as functions of disease duration and cognitive ability. Thus, the restoration of brain 
glucose availability and neuronal metabolism with GLP-1 or an analog potentially protects against cognitive 
impairment in Alzheimer’s disease.
Methods
Study design and participants. In the present investigation, we completed a 26-week, randomized, pla-
cebo-controlled, double-blinded intervention with liraglutide or placebo in patients with AD, recruited from 
dementia clinics in Central Denmark, with key clinical inclusion and exclusion criteria and administrative details 
listed by Gejl et al.27.
We assigned 38 patients to receive either the GLP-1 analog liraglutide (n = 18) or placebo (n = 20), as 
described by Gejl et al.27. Of these, 14 patients had PET with [18F]FDG before and after treatment, compared to 
19 patients who received placebo, all of whom completed the cognitive examination. Tomography sessions for 
CMRglc were incomplete in two patients, leaving 17 patients from the placebo group and 14 patients from the 
liraglutide group in the final analysis of [18F]FDG-derived radioactivity. Demographic and clinical characteristics 
are described in Gejl et al.27. The AD duration measure was determined as the time from definite diagnosis.
Patients willing to participate gave written informed consent. Safety data were monitored independently 
throughout the study period. The study was conducted according to the principles of the Helsinki Declaration. 
The Central Denmark Regional Committees on Biomedical Research Ethics, the Danish Data Protection 
Agency, and the Danish Medicines Agency approved the protocol59, with trial registration at ClinicalTrials.gov: 
NCT01469351, November 1, 2011. Participants attended a screening visit to assess eligibility followed by rand-
omization to liraglutide or placebo for 26 weeks. Liraglutide was administered as 0.6 mg subcutaneously daily for 
one week; hereafter 1.2 mg daily for one week, before final increase to 1.8 mg daily. The placebo group members 
received saline in similar volumes.
Positron Emission Tomography. The subjects underwent PET of [18F]FDG uptake and metabolism, as 
described in previous dynamic [18F]FDG studies of brain metabolism26,60.
Co-registration. We acquired anatomical images for co-registration with the 3 T Magnetom Tim Trio 
system (Siemens Healthcare, Erlangen, Germany) with 3D T1-weighted high-resolution anatomic scan of 
magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence. We co-registered PET images 
with individual MR images to an MR template, and evaluated the quality of each co-registration by visual inspec-
tion in 3 planes. PET and MR-images were co-registered and entered in Talairach space, and anatomical volumes 
of interest were used to extract time-activity-curves (TACs) from the dynamic PET images for the [18F]FDG 
analyses of cortex as a whole.
Cognitive Testing. We evaluated cognition by the “Brief cognitive examination” from the Wechsler Memory 
Scale (WMS-IV)61, the test examines examining orientation, time estimation, mental control, clock drawing, 
incidental recall, inhibition and verbal reproduction.
Kinetic Analysis. The primary outcome was the maximum glucose transport capacity of the BBB (Tmax.) 
assessed with [18F]FDG. We also determined magnitudes of unidirectional glucose extraction fraction (GEF) 
from measures of [18F]FDG uptake and blood flow, the latter as reported by Gejl et al.27. Using a 3-compartment 
model, we obtained values of ⁎K1 . (unidirectional clearance where symbols marked with asterisk indicate tracer 
[18F]FDG), ⁎k2 . (efflux rate constant), 
⁎k3  (phosphorylation rate constant) and Vb (volume of brain occupied by 
intravascular blood) for [18F]FDG. The absolute dephosphorylation flux and the absolute quantity of [18F]FDG 
were both considered negligible during the scanning period. In the use of [18F]FDG to trace glucose metabolism, 
the “lumped constant” (LC) is a necessary isotope correction factor that we set to the value of 0.7627. T ratio 
between unidirectional clearances of [18F]FDG and glucose (τ) was set at the value of 1.48 and the phosphoryla-
tion ratio (φ) at the value of 0962. T net clearance of [18F]FDG then is given by63,
=
+
⁎
⁎ ⁎
⁎ ⁎K
K k
k k( ) (1)
1 3
2 3
where K* and ⁎K1  are the net and unidirectional blood-brain clearances of [18F]FDG, and 
⁎k2 , and 
⁎k3  are the corre-
sponding rate constants of [18F]FDG-derived radioactivity exchanges between circulation and the [18F]FDG pre-
cursor pool mediated by GLUT1 and hexokinase. The unidirectional glucose flux from blood into brain was 
calculated from the unidirectional [18F]FDG clearance as,
τ= ⁎J K C / (2)a1 1
where J1 is the unidirectional flux of glucose (rather than [18F]FDG) from blood to brain, Ca is the arterial plasma 
glucose concentration, and τ is the affinity ratio of [18F]FDG to glucose for blood-brain transfer across the BBB. 
The net clearance of glucose by definition is
= ⁎K K /LC (3)
where LC is the “lumped constant”, defined above as the ratio of the net clearances of [18F]FDG and glucose, such 
that the net cerebral metabolic rate for glucose is calculated from the net [18F]FDG clearance as,
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= ⁎K CCMR /LC (4)aglc
such that the cerebral tissue glucose concentration Ctissue is
⁎τ= −C J k( CMR )/ (5)tissue 1 glc 2
and the flux of glucose from brain to blood, J2, is
= −J J CMR (6)2 1 glc
Here, the unidirectional glucose extraction fraction (GEF) by definition is K F/1 where F is cerebral blood flow, 
while the glucose utilization fraction (GUF), also by definition, is FCCMR /( )aglc . We determined the blood-brain 
unidirectional clearance, defined as,
=K J C/ (7)a1 1
from the values of flux and concentration, while the glucose clearance from brain tissue to the circulation (K2) 
likewise was determined from the brain-blood flux and brain tissue concentration of glucose, as,
=K J C/ (8)2 2 tissue
Michaelis-Menten analysis. Together, the two sets of values of clearance and corresponding fluxes (K1, J1 
and K2, J2) depend on the affinity and maximum transport capacity of glucose across the BBB, as implemented 
twice in the linearized Eadie-Hofstee Plot version of the Michaelis-Menten equation64–66, both for the blood-brain 
transfer direction,
= −J T K K (9)t1 max 1
and for the brain-blood transfer direction,
= −J T K K (10)t2 max 2
from which we calculated the parameters Tmax and Kt by multilinear regression, yielding a shared estimate of Kt 
for all members of the group and individual estimates of Tmax for each member.
Control group. We obtained a control estimate of the maximum glucose transport across the blood-brain 
barrier from published measurements by Kuwabara et al.29 that we analyzed in the same manner as the estimates 
in the four groups of patients with Alzheimer’s disease, after correction for the lower resolution and greater partial 
volume effect of PET before the 21st Century (radioactivities increased by 1.33 for cerebral cortex).
Statistics. We analyzed treatment group data in two ways: We analyzed changes of kinetic variables by paired 
t-tests within groups, and changes of Tmax with 2-way ANOVA of qui-squared with Tukey’s correction for mul-
tiple comparisons within and between groups. P-values less than 0.05 were considered indicative of significant 
difference. Spearman and Pearson’s r tests were used to evaluate correlations, implemented in GraphPad Prism 
(GraphPad Software, San Diego, CA) and PMOD (PMOD Technologies Ltd., Zürich, Switzerland).
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